Compile Data Set for Download or QSAR
maximum 50k data
Found 246 with Last Name = 'bhumralkar' and Initial = 'd'
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403726(CHEMBL2112936)
Affinity DataKi:  20nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075917(8N-(2-aminoethyl)-15-oxo-9a,10,11,12,13,13a,14,15-...)
Affinity DataKi:  45nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403725(CHEMBL2112326)
Affinity DataKi:  75nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075918(8N-[2-amino-(1R,2R)-cyclohexyl]-15-oxo-(9aS,13aS)-...)
Affinity DataKi:  86nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403726(CHEMBL2112936)
Affinity DataKi:  110nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075917(8N-(2-aminoethyl)-15-oxo-9a,10,11,12,13,13a,14,15-...)
Affinity DataKi:  160nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075918(8N-[2-amino-(1R,2R)-cyclohexyl]-15-oxo-(9aS,13aS)-...)
Affinity DataKi:  180nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403725(CHEMBL2112326)
Affinity DataKi:  200nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075921(8N-(2-aminoethyl)-15-oxo-(9aR,13aS)-11,12,13,15-te...)
Affinity DataKi:  270nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075924(13-Oxo-10,11,12,13-tetrahydro-9H-5,7,9,12-tetraaza...)
Affinity DataKi:  650nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075921(8N-(2-aminoethyl)-15-oxo-(9aR,13aS)-11,12,13,15-te...)
Affinity DataKi:  830nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 7(Homo sapiens (Human))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403726(CHEMBL2112936)
Affinity DataKi:  1.60E+3nMAssay Description:Binding affinity against 5-hydroxytryptamine 7 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075924(13-Oxo-10,11,12,13-tetrahydro-9H-5,7,9,12-tetraaza...)
Affinity DataKi:  2.05E+3nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(Homo sapiens (Human))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403726(CHEMBL2112936)
Affinity DataKi:  3.20E+3nMAssay Description:Binding affinity against dopamine D2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeuropeptide Y receptor type 1(Homo sapiens (Human))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403726(CHEMBL2112936)
Affinity DataKi:  4.20E+3nMAssay Description:Binding affinity against Neuropeptide Y receptor type 1 using [125I]-PYYMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075923(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid ((1R...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075920(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid ((1R...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 1(Rattus norvegicus (rat))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075919(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid (2-a...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075919(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid (2-a...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 6(Homo sapiens (Human))
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50403726(CHEMBL2112936)
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity against 5-hydroxytryptamine 6 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075925(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid dime...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075923(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid ((1R...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50075920(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid ((1R...)
Affinity DataKi: >1.00E+4nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 betaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCorticotropin-releasing factor receptor 2(Mus musculus)
Agouron Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM32001(7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid | 7-...)
Affinity DataKi: >1.00E+5nMAssay Description:Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 beta (30% inhibition at 100 uM)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM113428(US8633204, 127)
Affinity DataIC50:  0.480nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM50433038(CHEMBL2375957 | US8633204, 299)
Affinity DataIC50:  0.686nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113443(US8633204, 146)
Affinity DataIC50:  0.731nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113420(US8633204, 115)
Affinity DataIC50:  0.75nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113542(US8633204, 276)
Affinity DataIC50:  0.788nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113434(US8633204, 137)
Affinity DataIC50:  0.989nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113441(US8633204, 144)
Affinity DataIC50:  1.01nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113437(US8633204, 140)
Affinity DataIC50:  1.03nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113479(US8633204, 191)
Affinity DataIC50:  1.10nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113455(US8633204, 165)
Affinity DataIC50:  1.20nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113453(US8633204, 163)
Affinity DataIC50:  1.20nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113448(US8633204, 158)
Affinity DataIC50:  1.30nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113544(US8633204, 278)
Affinity DataIC50:  1.30nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113535(US8633204, 265)
Affinity DataIC50:  1.43nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113551(US8633204, 288)
Affinity DataIC50:  1.44nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113417(US8633204, 108)
Affinity DataIC50:  1.57nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM50433044(CHEMBL2375963 | US8633204, 304)
Affinity DataIC50:  1.58nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113543(US8633204, 277)
Affinity DataIC50:  1.59nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113461(US8633204, 171)
Affinity DataIC50:  1.60nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113495(US8633204, 217)
Affinity DataIC50:  1.60nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113469(US8633204, 180)
Affinity DataIC50:  1.60nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113526(US8633204, 254)
Affinity DataIC50:  1.70nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113432(US8633204, 135)
Affinity DataIC50:  1.77nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113541(US8633204, 274)
Affinity DataIC50:  1.80nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113489(US8633204, 207)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM113527(US8633204, 255)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:Compounds of the present invention were evaluated for potency against PI3-Kα using an in vitro kinase assay. PI3-Kα activity is measured in...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 246 total ) | Next | Last >>
Jump to: